Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 1995Expert Opinion on Investigational Drugs

Section Review: Cardiovascular & Renal: Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseases

View Full Paper
Ask AI
Bookmark
Share

Design

Review

Authors

JSJean‐Claude StocletLaboratoire d'HydrodynamiqueTKThérèse KeravisCentre National de la Recherche ScientifiqueNKNarcisse KomasInstitut Pasteur de Bangui

Discussion

Loading...

Member takes

Overview

PDE3 inhibitors warrant arrhythmia caution in heart failure; leaves open PDE4/5-selective targeting for antithrombotic effects pending trials.

Structured PICO

I
Intervention
Cyclic nucleotide phosphodiesterase (PDE) inhibitors, specifically PDE3, PDE4, and PDE5 inhibitors

This review highlights the differential roles of PDE isozymes in the cardiovascular system and the potential, as well as the risks (e.g., PDE3 inhibitors in heart failure), of selective PDE inhibitors as therapeutic targets.

Cite This Study

Stoclet et al. (1995) studied this question.

synapsesocial.com/papers/6a70d69075498292b70a50c2https://doi.org/10.1517/13543784.4.11.1081
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea‐pig peritoneal macrophages1993 · 62 citations
  2. 2Regulation of Cardiac L-Type Calcium Current by Phosphorylation and G Proteins1990 · 361 citations